Alternate Name(s):
Apo-Flecainide, Tambocor
Classification:
Antiaarhythmic
Original Date:
June 2014
Indications:
- Treatment of ventricular and supraventricular tachyarrhythmias
Administration:
- PO
- Avoid concurrent administration with feedings as dairy products (milk, infant formula) may interfere with the absorption of Flecainide
Dosage:
- 1-3 mg/kg/day divided Q8-12h
- Titrate dose to clinical response up to a maximum of 8 mg/kg/day or 200 mg/m2/day
- Allow 3 days between dosage increments to achieve new steady-state and to monitor clinical response
Formula for Body Surface Area (BSA):
Click here for Body Surface Area (BSA)
Dosage adjustment required in renal impairment. Refer to available references or clinical pharmacist for dosage adjustment.
Side Effects:
- CVS: proarrhythmic effects, QTc prolongation
- Hematology (rare): granulocytopenia, leukopenia, thrombocytopenia
- Respiratory: bronchospasm
Parameters to Monitor:
- Daily ECG until stable dose (monitoring QRS duration)
- HR
- CBC with differential
Reconstitution and Stability:
N/A
Compatibility:
N/A
References:
- Ferlini M, Colli AM, Bonanomi C, et al. Flecainide as First-Line Treatment for Supraventricular Tachycardia in Newborns. J Cardiovasc Med (Hagerstown), 2009, 10 (5): 372-5
- Price JF, Kertesz NJ, Snyder CS, et al. Flecainide and Sotalol: A New Combination Therapy for Refractory Supraventricular Tachycardia in Children < 1 Year of Age. J Am Coll Cardiol 2002; 39: 517-20
- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 20th Edition. Hudson: Lexi-Comp Inc; 2013